drugset
drugset / Trial / NCT00667966

Assess Efficacy in Subjects With Traumatic Spinal Cord Injury

NCT00667966 ↗

Phase 4 Completed 45 enrolled Bayer
RandomizedCrossoverDouble-blindTreatment

Summary

Assess efficacy of Vardenafil in patients with traumatic spinal cord injury

Timeline

Start
2005-07
Primary completion
—
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 10 mg —
Subject Vardenafil Small molecule 20 mg —

Indications

erectile dysfunction spinal cord injury